Research & Development

Our research addresses different aspects of EB pathogenesis, and we are utilizing different modalities to develop potential novel treatments for EB. We are developing the programs internally but are also open for partnering.

• Our gene therapy program EB01, currently in validation stage, is focused on the correction of casual mutations in EB subtypes.
• Program EB02 aims to identify small molecules able to target EB associated squamous cell carcinoma (SCC) utilizing phenotypic screening capabilities.
• Program EB03 focuses on bolstering cancer treatment for RDEB patients with clinically diagnosed SCC lesions.
• Program EB04 is an inhibitory antibody to modulate the immune system to treat SCC in EB patients.